Results 121 to 130 of about 103,009 (314)

Preparation and characterization of renal cell peptides from fetal rats for their antitumor activity

open access: yesFEBS Open Bio, EarlyView.
This study aimed to prepare renal cells (RCs) from fetal rats which were digested by enzymes. Candidate peptides RCPs were characterized by capillary HPLC and MS and their bioactivity was predicted using peptideranker. The predicted top 10 bioactive peptides were synthesized.
Zhe Zhang   +6 more
wiley   +1 more source

Phenotypic plasticity in a novel set of EGFR tyrosine kinase inhibitor‐adapted non‐small cell lung cancer cell lines

open access: yesFEBS Open Bio, EarlyView.
Phenotypic plasticity in a newly established set of EGFR inhibitor‐adapted NSCLC cell lines during adaptation and in established cell lines. Here, we introduce novel sublines of the EGFR‐mutant non‐small cell lung cancer (NSCLC) cell lines HCC827 and HCC4006 adapted to the EGFR kinase inhibitors gefitinib (HCC827rGEFI2μm, HCC4006rGEFI1μm), erlotinib ...
Tharsagini V. Nanthaprakash   +6 more
wiley   +1 more source

CD9‐association with PIP2 areas is regulated by a CD9 salt bridge

open access: yesFEBS Open Bio, EarlyView.
The tetraspanin CD9 has an intracellular salt bridge. If CD9 opens, open‐CD9 moves from PIP2‐rich areas to regions populated by its interaction partner EWI‐2. Hence, the state of the salt bridge regulates the distribution of CD9 and by this CD9‐EWI‐2 complex formation.
Yahya Homsi   +2 more
wiley   +1 more source

Polydatin ameliorates ovalbumin‐induced asthma in a rat model through NCOA4‐mediated ferroautophagy and ferroptosis pathway

open access: yesFEBS Open Bio, EarlyView.
In this research, a rat model of asthma was created using OVA, and polydatin served as an intervention. By inhibiting ferroautophagy mediated by NCOA4 and averting ferroptosis, polydatin has been demonstrated to reduce asthma. This work presents new ideas for investigating the mechanism of polydatin's ability to alleviate asthma, in addition to ...
Wei Li   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy